Clinical trials
Recurrent Low Grade Glioma clinical trials
Below are recruiting recurrent low grade glioma clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Birmingham, AlabamaAges 1–25 - NCT06660056RecruitingPhase 1
GC001 injection for returning or growing high-grade brain tumors
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06253234RecruitingPhase 1
DC vaccine for recurrent high-grade gliomas
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT07110246RecruitingPhase 2
Dabrafenib and trametinib for BRAF-mutated low-grade gliomas
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
Birmingham, AlabamaAges 1–25 - NCT06381570RecruitingEarly Phase 1
Vinblastine and tovorafenib for recurring pediatric low-grade glioma
This trial is testing a combination of two drugs, vinblastine and tovorafenib, for children and young adults (up to age 25) whose low-grade glioma has come back or worsened after prior treatment. It is for people whose tumor has a specific change in a gene called BRAF or CRAF.
Toronto, OntarioAges birth–25 years - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT04065776Recruiting
Proton therapy that avoids the hippocampus for slow brain tumors
This study tests a proton radiation plan designed to spare the hippocampus (a memory area) in children and teens with certain low-grade brain tumors. It may help deliver treatment to the tumor while reducing unwanted brain effects.
Rochester, MinnesotaAges 6–21 - NCT04267978RecruitingPhase 2
Test drug combination for recurrent brain tumor growth
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
BeijingAges 18–70 - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT05609994RecruitingPhase 1
Vorasidenib plus a peptide vaccine for recurrent low-grade glioma
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
Durham, North CarolinaAges 18 years+ - NCT06159478RecruitingPhase 2
Testing binimetinib for BRAF fusion brain tumors and pancreatic cancer
This trial tests a targeted drug, binimetinib, for people with low-grade glioma (a type of brain tumor) or pancreatic cancer that has a specific genetic change called a BRAF fusion. The drug aims to block signals that help these tumors grow.
Kashiwa, ChibaAges 12 years+ - NCT06712875RecruitingPhase 1/Phase 2
Brain cancer drug combo for kids with BRAF mutations
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
Washington D.C., District of ColumbiaAges 1–26 - NCT06964737RecruitingPhase 1
CAR T-cell therapy for recurrent brain tumors
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Columbus, OhioAges 18 years+ - NCT07506239Recruiting
Laser therapy for low-grade brain tumors in young people
This trial tests a laser treatment called LITT for low-grade glioma (a type of brain tumor) that has come back or is growing despite prior treatment. It aims to see if the laser is safe and effective in young people aged 2 to 25.
San Francisco, CaliforniaAges 2–25 - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT07441707RecruitingPhase 1
Tovorafenib for Japanese children and young adults with brain tumors
This study tests an experimental medicine called tovorafenib for children and young adults (6 months to 25 years) with Japanese ancestry whose low-grade brain tumors have returned or grown after prior treatment. The medicine targets tumors with a specific BRAF genetic change.
KanagawaAges 6 months–25 years - NCT03643549RecruitingPhase 1/Phase 2
Combination treatment for recurring brain cancer
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
BergenAges 18 years+ - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT06831773Recruiting
Carbon ion radiation for high-grade brain tumors
This trial tests a precise type of radiation called carbon ion radiotherapy for people with aggressive brain tumors (high-grade gliomas). It aims to see if this treatment is safe and effective for patients who have not had radiation to the head before.
Wuwei, GansuAges 14–80 - NCT07424092RecruitingPhase 2
Virus injection for children with recurrent brain tumors
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
UtrechtAges 1–25
Hear when a new Recurrent Low Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent low grade glioma?
- Yes. Clin2 currently lists 32 recruiting recurrent low grade glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent low grade glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent low grade glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.